ACD in inflammatory rheumatic diseases

Anemia of Chronic Disease

Volumn , Issue , 2005, Pages 633-658

  Kaltwasser, J P ^a   Arndt, U ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646241802     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Erslev AJ. Erythrocyte disorders-anemias related to unknown or multiple mechanisms. In: Williams WJ, Beutler E, Erselev AJ, Lichtman MA, eds. Hematology. 3rd ed. McGraw-Hill Book Company, 1983:522-528.
2. Mowat AG. Haematologic abnormalities in rheumatoid arthritis. Sem Arhritis Rheum 1971; 1:195-219.
3. Bennett RM. Haematological changes in rheumatoid disease. Clin Rheum Dis 1977; 3:433-465.
4. Remacha AF, Rodriguez-De La Serna A, Garcia-Die F, Geli C, Diaz C, Gimferrer E. Erythroid abnormalities in rheumatoid arthritis: the role of erythropoietin. J Rheumatol 1992; 19:1687-1691.
5. Davis D, Charles PJ, Potter A, Feldmann M, Maini N, Elliott MJ. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis a blockade. Br J Rheumatol 1997; 36:50-56.
6. Vila LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S. Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus. Lupus 1999; 8:279-286.
7. Rivero Puente A, Berasategui Calderon JI, Murie Carrillo de Albornoz JM, Rivero Marcotegui M, Garcia-Bragado Acin F. Giant cell arteritis and polymyalgia rheumatica: diagnosis and evolution of 90 cases. An Med Interna 2001; 18:191-194.
8. Frayha RA, Shulman LE, Stevens MB. Hematological abnormalities in scleroderma. A study of 180 cases. Acta Haematol 1980; 64:25-30.
9. Marks SH, Barnett M, Calin A. Ankylosing spondylitis in women and men: a case-control study. J Rheumatol 1983; 10:624-628.
10. Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJG. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990; 49:93-98.
11. Weiss G. Pathogenesis and treatment of anaemia of chronic diseases. Blood Rev 2002; 16:87-96.
12. Ward HP, Gordon B, Pisarczyk JC. Serum levels of erythropoietin in anemia associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest 1971; 50:332-335.
13. Peeters HR, Jongen-Lavrencic M, Raja AN, Ramdin HS, Vreugdenhil G, Breedveld FC. Course and characteristics of anemia in patients with RA of recent onset. Ann Rheum Dis 1996; 55:162-168.
14. Swaak AJG, van den Brink HG, Smeenk RJ, Manger K, Kaleden JR, Tosi S, Domljan Z, Rozman B, Logar D, Pokorny G, Kovacs L, Vlachoyiannopoulos PG, Moutsopoulos HM, Chwalinska-Sadowska H, Kiss E, Cikes N, Anic B, Schneider M, Fischer R, Bombardieri S, Mosca M, Graninger W, Smolen JS. Systemic lupus erythematosus. Disease outcome in patients with a disease duration at least 10 years: second evaluation. Lupus 2001; 10:51-58.
15. Manger K, Repp R, Jansen M, Geisselbrecht M, Wassmuth R, Westerdaal NAC, Pfahlberg A, Manger B, Kalden JR, van de Winkel JGJ. Ann Rheum Dis 2002; 61:786-792.
16. Voulgarelis M, Kokori SIG, Ioannidis JPA, Tzioufas AG, Kyriaki D, Moutsopoulos HM. Anaemia in systemic lupus erythematosus: aetiological profile and role of erythropoietin. Ann Rheum Dis 2000; 59:217-222.
17. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology 2003; 42:230-234.
18. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation-rate. J Rheumatol 1994; 21:1227-1237.
19. Pereira DA, Silva JA, Elkon KB, Hughes GRV. C-reactive protein levels in systemic lupus erythematosus: a classfication criterion? Arthritis Rheum 1980; 23:770-774.
20. Pincus T. Laboratory tests in rheumatic disorders. In: Klippel JH, Duppe PA, eds. Rheumatology. 2nd ed. London, Philadelphia, St. Louis, Sydney, Tokyo: Mosby, 1998 [chapter 10].
21. Baumann Kurer S, Seifert B, Michel B, Ruegg R, Fuhr J. Prediction of iron deficiency in chronic inflammatory rheumatic disease anaemia. Br J Haematol 1995; 91:820-826.
22. Suominen P, Möttönen T, Rajamäki A, Irjala K. Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anaemia. Arthritis Rheum 2000; 43:1016-1020.
23. Feelders RA, Vreugdenhil G, Manger B, van Eijk HG, Swaak AJG. Serum transferrin receptor levels in anaemia of rheumatoid arthritis and effects of iron chelation treatment. Eur J Haematol 1994; 52:61-62.
24. Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R. Zinc protoporphyrin in anemia of chronic disorders. Blood 1993; 81:1200-1204.
25. Garrett J, Worwood M. Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol 1994; 91:21-25.
26. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96:823-833.
27. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin. N Engl J Med 1974; 290:1213-1216.
28. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of anaemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
29. Koerper MA, Stempel DA, Dallman PR. Anemia in patients with juvenile arthritis. J Pediatr 1978; 92:930-933.
30. Davidson A, van derv Weyden MN, Fong H, Breidahl MJ, Ryan PFJ. Red cell ferritin content: a re-evaluation of indices for iron deficiency in the anaemia of rheumatoid arthritis. Br Med J 1984; 284:648-650.
31. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Möller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001; 28:2430-2436.
32. Lwin CT, Bishay M, Platts RG, Booth DA, Bowman SJ. The assessment of fatigue in primary Sjogren’s syndrome. Scand J Rheumatol 2003; 32:33-37.
33. Suurmeijer TP, Waltz M, Moum T, Guillemin F, van Sonderen FL, Briancon S, Sanderman R, van den Heuvel WJ. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum 2001; 45:111-121.
34. Brophy S, Cali A. Definition of disease flare in ankylosing spondylitis: the patient’s perspective. J Rheumatol 2002; 29:954-958.
35. Glaus A, Muller S. Haemoglobin and fatigue in cancer patients:inseparable twins? Schwei Med Wochenschr 2000; 130:471-477.
36. Salvarani C, Lasagni D, Casali B, Macchioni P, Boiardi L, Rossi F, Rivasi P, Portioli I. Recombinant human erythropoie- tin therapy in patients with the anemia of chronic disease. J Rheumatol 1991; 18:1168-1171.
37. Gudbjörnsson B, Hallgren R, Wide L, Birgegard G. Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Ann Rheum Dis 1992; 51:747-752.
38. Petterson T, Rosenloef K, Friman C, Mickos A, Teppo AM, Fyhrquist F. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scand J Rheumatol 1993; 22:188-193.
39. Murphy EA, Bell AL, Wojtulewski J, Brzeski M, Madhok R, Capell HA. Study of erythropoietin in treatment of anaemia in patients with rheumatoid arthritis. Br J Med 1994; 309:1337-1338.
40. Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJG. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999; 18:201-206.
41. Kendall R, Wasti A, Harvey A, Hill J, Chapman C, Norfolk DR, Pullar T. The relationship of hemoglobin to serumerythropoietin concentrations in the anaemia of rheumatoid arthritis: the effect of oral prednisolone. Br J Rheumatol 1993; 32:204-208.
42. Felson DT, Anderson JJ, Boers M. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-735.
43. Paulus HE, Egger MJ, Ward JR, Williams HJ. CSSRD: analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33:477-484.
44. Maini RN, Breedveld FC, Kalden JR, et al. The therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-1563.
45. Moreland LM, Cohen SB, Baumgartner S, et al. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis [abstr]. Arthritis Rheum 1999; 42:S401.
46. O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley L, Klassen LW, Wees S, Klein H, Moore GF. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287-1291.
47. Eleftherios C, Vamvakas EC, Morris R, Blajchman A. Deleterious clinical effects of transfusion-associated immunomodulation:fact or fiction? Blood 2001; 97:1180-1195.
48. van der Horst-Bruinsma IE, Huizinga TWJ, Lagaay EM, Hazes JMW, Breevfeld FC, Schreuder GMT, Tomson TAS, Zwinderman AH, van Rood JJ, de Vries RRP. The influence of partially HLA-matched blood transfusion on the disease activity of rheumatoid arthritis. Rheumatology 1999; 38:53-58.
49. Reddy PS, Lewis M. The adverse effect of intravenous iron-dextran in rheumatoid arthritis. Arthritis Rheum 1969; 12:454-457.
50. Lloyd KN, Williams P. Reactions to total dose infusion of iron dextran in rheumatoid arthritis. Br J Med 1970; 2:323-325.
51. Blake DR, Lunec J, Ahern M, Ring EFJ, Bradfield J, Gutteridge JMC. Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis 1985; 44:183-188.
52. Biemond P, Swaak AJG, van Eijk HG, Koster JF. Intraarticular ferritin-bound iron in rheumatoid arthritis. A factor that increases oxygen free radical-induced tissue destruction. Arthritis Rheum 1986; 29:1187-1193.
53. Giordano N, Sancasciani S, Borghi C, Fioravanti A, Marcolongo R. Antianemic and potential anti-inflammatory activity of desferrioxamine: possible usefulness in rheumatoid arthritis. Clin Exp Rheumatol 1986; 4:25-29.
54. Salvarani C, Baricchi R, Lasagni D, Boiardi L, Piccinini R, Brunati C, Macchioni P, Portioli I. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int 1996; 16:45-48.
55. Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Hematol 2001; 67:30-34.
56. Vreugdenhil G, Kontoghiorghes GJ, van Eijk HG, Swaak AJG. Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis: a possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one. Clin Exp Rheum 1992; 9:35-40.
57. Castriota-Scanderberg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Hematol 1997; 96:254-255.
58. Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343:1471-1472.
59. Mehta J, Singhal S, Revankar R, Walvalkar A, Chablani A, Mehta BC. Fatal systemic lupus erythematosus in patients taking oral iron chelator L1. Lancet 1991; 337:298.
60. Pavlovic-Kentera V, Ruvidic R, Milenkovic P, Marinkovic D. Erythropoietin in patients with anaemia in rheumatoid arthritis. Scand J Haematol 1979; 23:141-145.
61. Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, O’Neil VL, Pincus T. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin:clinical and in vitro studies. Arthritis Rheum 1989; 32:638-642.
62. Pincus T, Olsen NJ, Russell J, Wolfe F, Harris ER, Schnitzer TJ, Boccagno JA, Krantz SB. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89:161-168.
63. Takashina N, Kondo H, Kashiwaszaki S. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. J Rheumatol 1990; 17:885-887.
64. Kato Y, Takagi C, Tanaka J, Masaki Y, Furuya H. Effect of daily subcutaneous administration of recombinant erythropoietin on chronic anemia in rheumatoid arthritis. Int Med 1994; 33:193-197.
65. Peeters HRM, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJG. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996; 55:739-744.
66. Nordstroem D, Lindroth Y, Marsal L, Hafstroem I, Henrich C, Rantapaa-Dahlqvist S, Engstroem-Laurent A, Fyhrquist F, Friman C. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatol Int 1997; 17:67-73.
67. Nierman E, Zakrzewski K. Recognition and management of preoperative risk. Rheum Dis Clin North Am 1999; 25:585-622.
68. Mercuriali F, Gualtieri G, Singaglia L, Inghilleri G, Biffi E, Vinci A, Colotti MT, Barosi G, Lambertenghi Deliliers G. Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 1994; 34:501-506.
69. Matsui H, Shiraishi N, Yasuda T, Nezuka T. The effects of recombinant human erythropoietin on autologous blood donation in rheumatoid arthritis patients with anaemia. Clin Exp Rheumatol 1999; 17:69-74.
70. Bommer J, Ritz E, Weinreich T, Bommer G, Ziegler T. Subcutaneous erythropoietin. Lancet 1988; II:406.
71. Besareb A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2:1405-1416.
72. Kampf D, Kahl A, Passlick J, Pustelnik J, Eckardt KU, Ehmer B, Jacobs C, Baumelou A, Grabensee B, Gahl GM. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Contrib Nephrol 1989; 76:106-111.
73. Sunder-Plassmann G, Hoerl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10:2070-2076.
74. Kessler U, Betschel S, Woelfer S, Kaltwasser JP, Moeller B, Kaszkin M. Erythropoietin inhibits IL-1b stimulated arachidonic acid release from human synovial fibroblasts [abstr]. Arthritis Rheum 2002; 46:S259.